On July 28, 2026, San Diego-based Daré Bioscience (NASDAQ: DARE) announced a strategic collaboration with MyMenopauseRx, a telehealth platform focused exclusively on menopause care, making it a featured menopause-specific telehealth option for women exploring DARE to PLAY — the company's topically applied sildenafil cream for female sexual arousal. Under the arrangement, women can reach a board-certified menopause specialist through MyMenopauseRx alongside their arousal prescription, with options including lifestyle counseling and bioidentical hormone treatment, available by insurance or cash pay. Shares slid on the announcement.

Why It Matters

Female sexual dysfunction is the largest unmonetized indication in sexual health, and this deal is an honest admission of why: the bottleneck is not molecules, it's clinical context. Male sexual health built a multi-billion-dollar telehealth industry on a simple funnel — one symptom, one pill, one prescriber, done in ten minutes. Every attempt to run that playbook for female arousal has underperformed, because arousal complaints rarely arrive alone. They arrive tangled with hormonal transition, sleep debt, relationship dynamics and medication side effects, and a single-product intake form can't triage any of that. Daré's response is to stop trying to compress the encounter and instead route the patient to a specialist who can address the whole picture, accepting a longer, more expensive funnel in exchange for prescriptions that actually get refilled. If retention improves measurably, that structure — specialist partner as acquisition channel — becomes the reference architecture for the category. Two structural cautions are worth flagging for anyone doing diligence here. First, 503B compounding is a real regulatory and reimbursement constraint, not a footnote: a compounded product occupies a very different position with payers, pharmacies and marketing platforms than an FDA-approved drug, and it is a status that can shift. Second, the market read on the announcement was negative — the stock declined on the day — which suggests investors viewed a distribution partnership as thin relative to the capital needs of an actual commercial launch. Partnership announcements are cheap; prescription volume is not, and Medvantx dispensing hasn't started yet. The wider signal for the sector is convergence. Menopause telehealth, sexual arousal pharmacology and femtech commerce are collapsing into a single go-to-market. Hers entered menopause care with estrogen patches in April; Daré is entering menopause care from the arousal side. Whoever owns the perimenopausal patient relationship ends up owning the sexual wellness cross-sell — which is the same insight that put a Menopause Massager in plusOne's opening Ulta assortment two days earlier.

The product context matters for understanding the deal. DARE to PLAY is a topical sildenafil cream — the same active ingredient as Viagra, delivered locally rather than systemically — launched commercially in December 2025 as a Section 503B compounded product. There is no FDA-approved pharmaceutical therapy for female sexual arousal disorder, which makes DARE to PLAY, per the company's positioning, the first clinically studied, formulation-specific option a woman can obtain through a licensed clinician. Pre-fulfillment prescribing became available in all 50 states on February 11, 2026, and dispensing through Medvantx fulfillment infrastructure is targeted to begin later in summer 2026. Daré has said interest from the provider community at the ACOG annual conference in Q1 2026 reinforced its view that clinician advocacy will drive commercial momentum.

The strategic logic Daré articulated is a candid diagnosis of its own conversion problem. Women seeking help with arousal are frequently somewhere in the perimenopause or menopause transition, where changes in sexual function coexist with disrupted sleep, mood shifts, cognitive changes and energy loss. A product-only access model — here is a cream, here is a questionnaire — leaves that broader clinical picture unaddressed, which the company acknowledges can cap both conversion and retention. The MyMenopauseRx option now sits alongside DARE to PLAY's existing telehealth questionnaire and the option to consult one's own provider, giving three distinct pathways to a prescription.

Daré is explicit that this is a template rather than a one-off, describing the collaboration as "a foundation for additional strategic relationships across women's health" and framing the broader ambition as building a trusted women's health ecosystem spanning products, education and access to care — the DARE Health Hub. In other words, a small-cap biotech is attempting to become a channel, not just a manufacturer.

Sources

Update — 2026-07-30

Initial entry — story first created.

Update — 2026-09-03

The cream is now actually prescribable — and we finally have a price. Trade coverage on September 1, 2026 (Contemporary OB/GYN and Urology Times, both reporting a Daré Bioscience news release) confirmed DARE to PLAY Sildenafil Cream has moved from "coming soon" to commercially available for prescribing in a first tranche of states: Connecticut, Florida, Indiana, Missouri, New Hampshire, New Jersey, Oregon, Pennsylvania, Rhode Island and Utah, with shipments quoted at within 45 days of order placement. Daré says availability expands from there.

The regulatory posture is the thing to understand. This is not an FDA-approved drug. DARE to PLAY is being sold as a Section 503B compounded product manufactured through an outsourcing facility while Daré separately pursues an FDA approval pathway — the same structural play that made compounded GLP-1s and compounded hormone therapy mass-market categories in 2025–26. Daré frames it as the first topical sildenafil formulation developed for women offered through a 503B facility. CEO Sabrina Martucci Johnson's positioning is explicitly comparative: "When Viagra was approved in 1998, it revolutionized sexual medicine for men. But for women, comparable progress on enhancing the natural arousal sensations has stalled for nearly three decades."

Pricing and channel. Speaking at the company's virtual investor tour in late August (reported August 29), Johnson said DARE to PLAY is expected to price at $99 per tube, with each tube containing 10 doses — roughly $10 a dose. Fulfillment, telehealth access, payment processing and patient education all route through the Daré Health Hub, alongside clinician offices and third-party telehealth partners including the MyMenopauseRx tie-up covered in the original entry. Daré guided to initial DARE to PLAY revenue in Q3 2026.

The evidence base, stated plainly. Daré cites genital blood flow increases within 10–15 minutes and improvement on validated arousal endpoints, with findings published in Obstetrics and Gynecology and the Journal of Sexual Medicine, plus the Phase 1 postmenopausal pharmacokinetic data published in Menopause on August 26 (covered separately). San Diego Sexual Medicine's Irwin Goldstein, quoted in the company announcement, framed the appeal as research backing in a category dominated by consumer marketing. The honest caveat: exploratory and Phase 2b data supporting a compounded product is a materially weaker evidentiary position than an FDA approval, and Daré is the one drawing the Viagra comparison.

New Sources